pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
392
stories
16d
Bourla expects no changes to MFN deals after midterms
endpoints
16d
Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
biospace
16d
STAT+: Who will get the first psychedelic approved?
stat
16d
Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slide
endpoints
16d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
16d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
17d
OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M
fiercebiotech
17d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
17d
Can Saudi Arabia's burgeoning biotech hub withstand geopolitical pressures?
biospace
20d
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
biospace
20d
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
biospace
20d
AstraZeneca cuts early-phase prostate cancer pipeline
fiercebiotech
21d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
21d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
21d
Biopharma cuts at manufacturing plants expected to affect 4,000+
biospace
22d
Pfizer India site closure risks exacerbating cancer drug shortages
endpoints
22d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
23d
Alphabet’s GV is one of biotech’s most influential corporate investors
biospace
24d
ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
biospace
25d
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
endpoints
28d
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
28d
Pfizer details mixed Lyme disease vaccine data
endpoints
28d
Biohaven’s previously rejected rare disease drug to get fresh FDA review
biopharma dive
28d
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
29d
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
Oct 20, 26
Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO
endpoints
Oct 20, 26
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
Oct 20, 26
Alnylam bulls and bears fight it out after business-shaking guidance cut
biospace
Oct 20, 26
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
fiercebiotech
Oct 19, 26
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
← prev
page 3 of 14
next →